These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

594 related articles for article (PubMed ID: 29500065)

  • 21. Cabazitaxel multiple rechallenges in metastatic castration-resistant prostate cancer.
    Pobel C; Auclin E; Teyssonneau D; Laguerre B; Cancel M; Boughalem E; Noel J; Brachet PE; Maillet D; Barthelemy P; Helissey C; Thibault C; Oudard S
    Cancer Med; 2021 Sep; 10(18):6304-6309. PubMed ID: 34382352
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Patient Preference Between Cabazitaxel and Docetaxel for First-line Chemotherapy in Metastatic Castration-resistant Prostate Cancer: The CABADOC Trial.
    Baciarello G; Delva R; Gravis G; Tazi Y; Beuzeboc P; Gross-Goupil M; Bompas E; Joly F; Greilsamer C; Hon TNT; Barthelemy P; Culine S; Berdah JF; Deblock M; Ratta R; Flechon A; Cheneau C; Maillard A; Martineau G; Borget I; Fizazi K;
    Eur Urol; 2022 Mar; 81(3):234-240. PubMed ID: 34789394
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sequencing of Taxanes and New Androgen-targeted Therapies in Metastatic Castration-resistant Prostate Cancer: Results of the International Multicentre Retrospective CATS Database.
    Delanoy N; Hardy-Bessard AC; Efstathiou E; Le Moulec S; Basso U; Birtle A; Thomson A; Krainer M; Guillot A; De Giorgi U; Hasbini A; Daugaard G; Bahl A; Chowdhury S; Caffo O; Beuzeboc P; Spaeth D; Eymard JC; Fléchon A; Alexandre J; Helissey C; Butt M; Priou F; Lechevallier É; Deville JL; Goupil MG; Morales R; Thiery-Vuillemin A; Gavrikova T; Barthelemy P; Sella A; Fizazi K; Baciarello G; Fererro JM; Laguerre B; Verret B; Hans S; Oudard S
    Eur Urol Oncol; 2018 Dec; 1(6):467-475. PubMed ID: 31158090
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Germline DNA-repair Gene Mutations and Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Receiving First-line Abiraterone and Enzalutamide.
    Antonarakis ES; Lu C; Luber B; Liang C; Wang H; Chen Y; Silberstein JL; Piana D; Lai Z; Chen Y; Isaacs WB; Luo J
    Eur Urol; 2018 Aug; 74(2):218-225. PubMed ID: 29439820
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment Outcomes and Tumor Loss of Heterozygosity in Germline DNA Repair-deficient Prostate Cancer.
    Annala M; Struss WJ; Warner EW; Beja K; Vandekerkhove G; Wong A; Khalaf D; Seppälä IL; So A; Lo G; Aggarwal R; Small EJ; Nykter M; Gleave ME; Chi KN; Wyatt AW
    Eur Urol; 2017 Jul; 72(1):34-42. PubMed ID: 28259476
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Custirsen (OGX-011) combined with cabazitaxel and prednisone versus cabazitaxel and prednisone alone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (AFFINITY): a randomised, open-label, international, phase 3 trial.
    Beer TM; Hotte SJ; Saad F; Alekseev B; Matveev V; Fléchon A; Gravis G; Joly F; Chi KN; Malik Z; Blumenstein B; Stewart PS; Jacobs CA; Fizazi K
    Lancet Oncol; 2017 Nov; 18(11):1532-1542. PubMed ID: 29033099
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Weekly cabazitaxel plus prednisone is effective and less toxic for 'unfit' metastatic castration-resistant prostate cancer: Phase II Spanish Oncology Genitourinary Group (SOGUG) trial.
    Climent MÁ; Pérez-Valderrama B; Mellado B; Fernández Parra EM; Fernández Calvo O; Ochoa de Olza M; Muinelo Romay L; Anido U; Domenech M; Hernando Polo S; Arranz Arija JÁ; Caballero C; Juan Fita MJ; Castellano D
    Eur J Cancer; 2017 Dec; 87():30-37. PubMed ID: 29102858
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy outcomes by baseline prostate-specific antigen quartile in the AFFIRM trial.
    Saad F; de Bono J; Shore N; Fizazi K; Loriot Y; Hirmand M; Franks B; Haas GP; Scher HI
    Eur Urol; 2015 Feb; 67(2):223-30. PubMed ID: 25171902
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prognostic Value of the Modeled Prostate-Specific Antigen KELIM Confirmation in Metastatic Castration-Resistant Prostate Cancer Treated With Taxanes in FIRSTANA.
    Carrot A; Oudard S; Colomban O; Fizazi K; Maillet D; Sartor O; Freyer G; You B
    JCO Clin Cancer Inform; 2024 Feb; 8():e2300208. PubMed ID: 38364191
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prognostic Impact of Total Plasma Cell-free DNA Concentration in Androgen Receptor Pathway Inhibitor-treated Metastatic Castration-resistant Prostate Cancer.
    Fettke H; Kwan EM; Bukczynska P; Ng N; Nguyen-Dumont T; Southey MC; Davis ID; Mant A; Parente P; Pezaro C; Hauser C; Azad AA
    Eur Urol Focus; 2021 Nov; 7(6):1287-1291. PubMed ID: 32739405
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognostic model predicting metastatic castration-resistant prostate cancer survival in men treated with second-line chemotherapy.
    Halabi S; Lin CY; Small EJ; Armstrong AJ; Kaplan EB; Petrylak D; Sternberg CN; Shen L; Oudard S; de Bono J; Sartor O
    J Natl Cancer Inst; 2013 Nov; 105(22):1729-37. PubMed ID: 24136890
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prostate-specific Antigen Decline After 4 Weeks of Treatment with Abiraterone Acetate and Overall Survival in Patients with Metastatic Castration-resistant Prostate Cancer.
    Rescigno P; Lorente D; Bianchini D; Ferraldeschi R; Kolinsky MP; Sideris S; Zafeiriou Z; Sumanasuriya S; Smith AD; Mehra N; Jayaram A; Perez-Lopez R; Mateo J; Parker C; Dearnaley DP; Tunariu N; Reid A; Attard G; de Bono JS
    Eur Urol; 2016 Nov; 70(5):724-731. PubMed ID: 26965561
    [TBL] [Abstract][Full Text] [Related]  

  • 33. PSA time to nadir as a prognostic factor of first-line docetaxel treatment in castration-resistant prostate cancer: evidence from patients in Northwestern China.
    Wu KJ; Pei XQ; Tian G; Wu DP; Fan JH; Jiang YM; He DL
    Asian J Androl; 2018; 20(2):173-177. PubMed ID: 28905815
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cabazitaxel Versus Docetaxel As First-Line Therapy for Patients With Metastatic Castration-Resistant Prostate Cancer: A Randomized Phase III Trial-FIRSTANA.
    Oudard S; Fizazi K; Sengeløv L; Daugaard G; Saad F; Hansen S; Hjälm-Eriksson M; Jassem J; Thiery-Vuillemin A; Caffo O; Castellano D; Mainwaring PN; Bernard J; Shen L; Chadjaa M; Sartor O
    J Clin Oncol; 2017 Oct; 35(28):3189-3197. PubMed ID: 28753384
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The influence of prior abiraterone treatment on the clinical activity of docetaxel in men with metastatic castration-resistant prostate cancer.
    Schweizer MT; Zhou XC; Wang H; Bassi S; Carducci MA; Eisenberger MA; Antonarakis ES
    Eur Urol; 2014 Oct; 66(4):646-52. PubMed ID: 24491307
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Expression of AR-V7 and ARv
    Tagawa ST; Antonarakis ES; Gjyrezi A; Galletti G; Kim S; Worroll D; Stewart J; Zaher A; Szatrowski TP; Ballman KV; Kita K; Tasaki S; Bai Y; Portella L; Kirby BJ; Saad F; Eisenberger MA; Nanus DM; Giannakakou P
    Clin Cancer Res; 2019 Mar; 25(6):1880-1888. PubMed ID: 30301829
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The influence of treatment sequence in the prognostic value of TMPRSS2-ERG as biomarker of taxane resistance in castration-resistant prostate cancer.
    Marín-Aguilera M; Reig Ò; Milà-Guasch M; Font A; Domènech M; Rodríguez-Vida A; Carles J; Suárez C; Del Alba AG; Jiménez N; Victoria I; Sala-González N; Ribal MJ; López S; Etxaniz O; Anguera G; Maroto P; Fernández PL; Prat A; Mellado B
    Int J Cancer; 2019 Oct; 145(7):1970-1981. PubMed ID: 30807643
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naïve Prostate Cancer in the GETUG-AFU 15 Phase 3 Trial.
    Lavaud P; Gravis G; Foulon S; Joly F; Oudard S; Priou F; Latorzeff I; Mourey L; Soulié M; Delva R; Krakowski I; Laguerre B; Théodore C; Ferrero JM; Beuzeboc P; Habibian M; Rolland F; Deplanque G; Pouessel D; Zanetta S; Berdah JF; Dauba J; Baciuchka M; Platini C; Linassier C; Tubiana-Mathieu N; Machiels JP; Kouri CE; Ravaud A; Suc E; Eymard JC; Hasbini A; Bousquet G; Culine S; Boher JM; Tergemina-Clain G; Legoupil C; Fizazi K
    Eur Urol; 2018 May; 73(5):696-703. PubMed ID: 29074061
    [TBL] [Abstract][Full Text] [Related]  

  • 39. cfDNA as a Prognostic Marker of Response to Taxane Based Chemotherapy in Patients with Prostate Cancer.
    Kienel A; Porres D; Heidenreich A; Pfister D
    J Urol; 2015 Oct; 194(4):966-71. PubMed ID: 25896555
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy of enzalutamide following abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer patients.
    Azad AA; Eigl BJ; Murray RN; Kollmannsberger C; Chi KN
    Eur Urol; 2015 Jan; 67(1):23-29. PubMed ID: 25018038
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 30.